MAO-A and MAO-B activities in rat striatum, frontal cortex and liver are unaltered after long-term treatment with fluvoxamine and desipramine.
In the course of investigating the mechanisms underlying the beneficial effect of fluvoxamine augmentation on negative symptoms of schizophrenia, the authors found a reduction in human platelet monoamine oxidase-B activity after 5 weeks of treatment. This unexpected finding raised the possibility that MAO activity may be one of the factors altered by chronic tricyclic or SSRI antidepressant treatment. The current study examined the effect of long-term administration, up to 6 weeks, of fluvoxamine, desipramine or saline on MAO-A and MAO-B activities in rat striatum, frontal cortex and liver. No differences were noted between drug-treated groups and their saline-treated controls. The hypothesis that long-term treatment with tricyclic and SSRI antidepressants alters MAO activity was not supported. MAO is not among proteins whose activity may be altered by chronic tricyclic or SSRI antidepressant treatment.
Silver
H
H
Flugelman (Mazra) Psychiatric Hospital, Doar Na Ashrat, Israel.
Youdim
M B
MB
D000818:Animals; D001792:Blood Platelets / Q000201:enzymology; D003342:Corpus Striatum / Q000201:enzymology*; D003891:Desipramine / Q000494:pharmacology*; D016666:Fluvoxamine / Q000494:pharmacology; D005625:Frontal Lobe / Q000201:enzymology*; D006801:Humans; D007527:Isoenzymes / Q000187:drug effects / Q000378:metabolism; D008099:Liver / Q000201:enzymology*; D008297:Male; D008995:Monoamine Oxidase / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley
D007527:Isoenzymes; D008995:Monoamine Oxidase; D016666:Fluvoxamine; D003891:Desipramine